Novo Nordisk A S annual operating income
2019
2020
2021
2022
2023
2024
2025
Novo Nordisk A S Operating Income Growth & History (NVO)
Novo Nordisk A S's operating income was kr127.66B for fiscal 2025.
View full Novo Nordisk A S company overviewNovo Nordisk A S annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | kr127.66B | −kr681.0M | −0.53% |
| 2024 | 2024-12-31 | kr128.34B | kr25.77B | +25.12% |
| 2023 | 2023-12-31 | kr102.57B | kr27.77B | +37.11% |
| 2022 | 2022-12-31 | kr74.81B | kr16.16B | +27.56% |
| 2021 | 2021-12-31 | kr58.64B | kr4.52B | +8.35% |
| 2020 | 2020-12-31 | kr54.13B | kr1.64B | +3.13% |
| 2019 | 2019-12-31 | kr52.48B | — | — |
Novo Nordisk A S quarterly operating income
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | kr27.06B | −kr6.39B | −19.10% |
| Q1 2026 | 2026-03-31 | kr59.62B | kr20.83B | +53.69% |
| Q4 2025 | 2025-12-31 | kr31.74B | −kr5.00B | −13.61% |
| Q3 2025 | 2025-09-30 | kr23.68B | −kr10.14B | −29.98% |
| Q2 2025 | 2025-06-30 | kr33.45B | kr7.51B | +28.98% |
| Q1 2025 | 2025-03-31 | kr38.79B | kr6.95B | +21.81% |
| Q4 2024 | 2024-12-31 | kr36.74B | — | — |
| Q3 2024 | 2024-09-30 | kr33.82B | — | — |
| Q2 2024 | 2024-06-30 | kr25.93B | — | — |
| Q1 2024 | 2024-03-31 | kr31.85B | — | — |
Novo Nordisk A S operating income trends
Over the last five fiscal years, Novo Nordisk A S's operating income increased from kr54.13B to kr127.66B, a change of kr73.53B. The latest reported quarter, Q2 2026, shows kr27.06B.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novo Nordisk A S source filings ↗Community posts
Novo Nordisk reports positive STEP Young results in children aged 6 to under 12
Novo Nordisk announced first STEP Young Phase 3 results on 7 September 2026. Trial design and outcome The randomised, double-blind study involved 165 children aged 6 to under 12, comparing weekly semaglutide with placebo. Both groups receiv ...